We also evaluated CF following Pip4k2c modRNA delivery and found reduced fibrosis area (Figure 3m,n), inhibited expression of TGFβ1 and its target genes (Figure 3o), and fewer matrix MMP's (Figure 3p) 21 days after TAC in Pip4k2c modRNA‐treated hearts as compared to controls. This evidence concerns the gene TGFB1 and cystic fibrosis.